CA2503346C - Acide nucleique 24p4c12 et proteine correspondante utilises dans le traitement et la detection du cancer - Google Patents

Acide nucleique 24p4c12 et proteine correspondante utilises dans le traitement et la detection du cancer Download PDF

Info

Publication number
CA2503346C
CA2503346C CA2503346A CA2503346A CA2503346C CA 2503346 C CA2503346 C CA 2503346C CA 2503346 A CA2503346 A CA 2503346A CA 2503346 A CA2503346 A CA 2503346A CA 2503346 C CA2503346 C CA 2503346C
Authority
CA
Canada
Prior art keywords
protein
cancer
peptide
amino acid
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA2503346A
Other languages
English (en)
Other versions
CA2503346A1 (fr
Inventor
Arthur B. Raitano
Karen Jane Meyrick Morrison
Wangmao Ge
Pia M. Challita-Eid
Aya Jakobovits
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Agensys Inc
Original Assignee
Agensys Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agensys Inc filed Critical Agensys Inc
Publication of CA2503346A1 publication Critical patent/CA2503346A1/fr
Application granted granted Critical
Publication of CA2503346C publication Critical patent/CA2503346C/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

L'invention concerne un nouveau gène 024P4C12 (également nommé 24P4C12), sa protéine codée, ainsi que ses variants. Le gène 24P4C12 présente une expression tissulaire spécifique pour un tissu adulte normal, et est exprimé de manière aberrante dans les cancers énumérés dans la Table I. Le 24P4C12 constitue une cible diagnostique, pronostique, prophylactique et/ou thérapeutique contre le cancer. Le gène 24P4C12 ou un fragment de celui-ci, ou sa protéine codée, ou des variants ou un fragment de celle-ci, peuvent être utilisés pour déclencher une réponse immunitaire humorale ou cellulaire, et des anticorps ou des lymphocytes T réagissant avec le 24P4C12 peuvent être utilisés dans l'immunisation active ou passive.
CA2503346A 2002-11-27 2002-11-27 Acide nucleique 24p4c12 et proteine correspondante utilises dans le traitement et la detection du cancer Expired - Lifetime CA2503346C (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2002/038264 WO2004050828A2 (fr) 2002-11-27 2002-11-27 Acide nucleique 24p4c12 et proteine correspondante utilises dans le traitement et la detection du cancer

Publications (2)

Publication Number Publication Date
CA2503346A1 CA2503346A1 (fr) 2004-06-17
CA2503346C true CA2503346C (fr) 2014-03-18

Family

ID=32467113

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2503346A Expired - Lifetime CA2503346C (fr) 2002-11-27 2002-11-27 Acide nucleique 24p4c12 et proteine correspondante utilises dans le traitement et la detection du cancer

Country Status (6)

Country Link
EP (1) EP1565200A4 (fr)
JP (1) JP2006508163A (fr)
AU (3) AU2002352976B2 (fr)
CA (1) CA2503346C (fr)
IL (1) IL167892A (fr)
WO (1) WO2004050828A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2185574E (pt) * 2007-09-07 2013-08-26 Agensys Inc Anticorpos e moléculas relacionadas que se ligam a proteínas 24p4c12
US8309093B2 (en) * 2009-03-06 2012-11-13 Agensys, Inc. Antibody drug conjugates (ADC) that bind to 24P4C12 proteins
JP2013049646A (ja) * 2011-08-30 2013-03-14 Tokyo Medical Univ 癌治療剤
KR20180059922A (ko) 2015-10-02 2018-06-05 유니버시티 오브 코펜하겐 히스톤 리더 도메인을 차단하는 소분자
CN109073635A (zh) 2016-01-25 2018-12-21 豪夫迈·罗氏有限公司 用于测定t细胞依赖性双特异性抗体的方法
CN119086940A (zh) * 2017-04-28 2024-12-06 朋友股份有限公司 变态反应的抗原及其表位

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
EP0206448B1 (fr) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hémoglobine liée à un poly(oxyde d'alkylène)
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
EP0452457B1 (fr) 1989-11-03 1997-08-20 Vanderbilt University Procede d'administration in vivo de genes etrangers fonctionnels
US5279833A (en) 1990-04-04 1994-01-18 Yale University Liposomal transfection of nucleic acids into animal cells
US5204253A (en) 1990-05-29 1993-04-20 E. I. Du Pont De Nemours And Company Method and apparatus for introducing biological substances into living cells
SE9002480D0 (sv) 1990-07-23 1990-07-23 Hans Lilja Assay of free and complexed prostate-specific antigen
EP0646178A1 (fr) 1992-06-04 1995-04-05 The Regents Of The University Of California Cassette d'expression avec des regious regulatrices fonctionnelles chez le mammifere hote
US5679647A (en) 1993-08-26 1997-10-21 The Regents Of The University Of California Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
US5804566A (en) 1993-08-26 1998-09-08 The Regents Of The University Of California Methods and devices for immunizing a host through administration of naked polynucleotides with encode allergenic peptides
DE69435171D1 (de) 1993-09-14 2009-01-08 Pharmexa Inc Pan dr-bindeproteinen zur erhöhung der immunantwort
US5739118A (en) 1994-04-01 1998-04-14 Apollon, Inc. Compositions and methods for delivery of genetic material
US5919652A (en) 1994-11-09 1999-07-06 The Regents Of The University Of California Nucleic acid molecules comprising the prostate specific antigen (PSA) promoter and uses thereof
US5736524A (en) 1994-11-14 1998-04-07 Merck & Co.,. Inc. Polynucleotide tuberculosis vaccine
US5962428A (en) 1995-03-30 1999-10-05 Apollon, Inc. Compositions and methods for delivery of genetic material
US5922687A (en) 1995-05-04 1999-07-13 Board Of Trustees Of The Leland Stanford Junior University Intracellular delivery of nucleic acids using pressure
CU22559A1 (es) 1996-01-17 1999-05-03 Ct Ingenieria Genetica Biotech Sistema de expresión de antígenos heterologos en e. coli como proteínas de fusión
CN1225590A (zh) 1996-03-11 1999-08-11 埃皮曼尼公司 对hla分子结合亲和力提高的肽
JP2000516090A (ja) 1996-07-26 2000-12-05 スローン―ケッタリング インスティチュート フォー キャンサー リサーチ 遺伝子的免疫化のための方法と試薬
US5840501A (en) 1996-10-25 1998-11-24 Bayer Corporation Determination of cPSA
JP2001512013A (ja) * 1997-08-01 2001-08-21 ジェンセット 前立腺に発現される分泌タンパク質の５’ｅｓｔ
WO2000061746A1 (fr) * 1999-04-12 2000-10-19 Agensys, Inc. 13 proteines transmembranaires exprimees dans le cancer de la prostate
US6943235B1 (en) * 1999-04-12 2005-09-13 Agensys, Inc. Transmembrane protein expressed in prostate cancer
JP2004500814A (ja) * 1999-12-23 2004-01-15 インサイト・ゲノミックス・インコーポレイテッド 輸送体及びイオンチャネル

Also Published As

Publication number Publication date
AU2009208065B2 (en) 2012-05-24
AU2002352976B2 (en) 2007-11-08
JP2006508163A (ja) 2006-03-09
WO2004050828A3 (fr) 2004-12-09
WO2004050828A2 (fr) 2004-06-17
CA2503346A1 (fr) 2004-06-17
EP1565200A4 (fr) 2009-06-24
AU2009208065A1 (en) 2009-08-27
AU2008200628A1 (en) 2008-03-06
EP1565200A2 (fr) 2005-08-24
AU2002352976A1 (en) 2004-06-23
IL167892A (en) 2012-06-28
AU2008200628B2 (en) 2009-05-07

Similar Documents

Publication Publication Date Title
CA2493923C (fr) Acides nucleiques et proteines correspondantes intitulees 191p4d12(b) utilises dans le traitement et la detection du cancer
CA2462653C (fr) Acide nucleique et proteine correspondante 161p2f10b utiles dans le traitement et le depistage du cancer
CA2459318C (fr) Acide nucleique et proteine correspondante designes par steap-1 utiles dans le traitement et la detection du cancer
US7622564B2 (en) Prostate stem cell antigen (PSCA) variants and subsequences thereof
AU2010226920B2 (en) Nucleic acid and corresponding protein entitled 161P2F10B useful in treatment and detection of cancer
US7968090B2 (en) Nucleic acids and corresponding proteins entitled 191P4D12(b) useful in treatment and detection of cancer
US8124741B2 (en) Antibodies to tumor associated proteins
CA2481503A1 (fr) Acide nucleique et proteine correspondante 98p4b6 utilises dans le traitement et la detection du cancer
AU2009208065B2 (en) Nucleic acid and corresponding protein entitled 24P4C12 useful in treatment and detection of cancer
CA2496566A1 (fr) Acide nucleique et proteine correspondante denommes 98p4b6, pour traitement et detection du cancer
HK1152714B (en) Nucleic acid and corresponding protein entitled steap-1 useful in treatment and detection of cancer

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20221128